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Introduction
Various levels of oral colchicine resistance is still an unmet
challenge of FMF treatment. IV colchicine was shown to
be effective and safe answer, but its long term outcomes
are not known.
Objectives
To determine long term effectiveness and safety of IV
colchicine treatment in oral colchicine refractory or
intolarant FMF patients.
Methods
Included were all patients, experiencing ≥1 attack per
month, or intolerant to adequate dose of oral colchicin,
for which they receive IV colchicine (pharmacy prepara-
tion under government control) for at least 1 year. Retrie-
val of data was based on patient interviews, files and a
detailed questionnaire, focusing on clinical, demographic
and genetic data. Effect of colchicine was determined, by
computing attack rate, duration and intensity, the later
with 1-10 scale.
Results
Ten of 11 identified patients, on long term IV colchicine
treatment, consented to partake. Treatment lasted 3.6 ±2.7
(1- 10) years. More than 50% reduction in the rate of
abdominal, chest, joint and skin attacks was noted by 8 of
10 patients. The intensity of the attacks dropped by a
mean of 50±22% and the duration by 40±20%. In 4
patients the favorable effect has decreased partially, but in
only one treatment was stopped for this reason. Treatment
was terminated in another 2 for loss of venous access (1)
and for paresthesis. Adverse effects included diarrhea
(1 patient), vomiting (2), injection site pain (3), headache
(1), muscle pain (1), injection site phlebitis (1) and arm
paresthesis (1).
Conclusion
Long term parenteral colchicine treatment proved
effective and safe. Downloading I.V. colchicine off the
shelves due to intoxication associated with uncontrolled
and unjustified use for back pain, had serious negative
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